RARE DISEASE
Congenital generalized lipodystrophy
Congenital generalized lipodystrophy
Congenital generalized lipodystrophy
Synonyms: BSCL, Berardinelli-Seip congenital lipodystrophy, Berardinelli-Seip syndrome, CGL, Lipoatrophic diabetes
Synonyms: BSCL, Berardinelli-Seip congenital lipodystrophy, Berardinelli-Seip syndrome, CGL, Lipoatrophic diabetes
Synonyms: BSCL, Berardinelli-Seip congenital lipodystrophy, Berardinelli-Seip syndrome, CGL, Lipoatrophic diabetes
Drug discovery
4
drugs
With orphan designations
Overview
Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by near-total absence of adipose tissue from birth, leading to severe metabolic complications including insulin resistance, diabetes mellitus, hypertriglyceridemia, and hepatic steatosis. Four subtypes (CGL1-4) are defined by mutations in AGPAT2, BSCL2, CAV1, or CAVIN1 genes. Clinical features include acromegaloid facies, muscular hypertrophy, and hepatomegaly. Complications involve cardiomyopathy, pancreatitis, and hepatic cirrhosis, with reduced life expectancy if untreated [1][2][4].
Burden
Early-onset metabolic derangements (e.g., diabetes by adolescence) drive end-organ damage (liver cirrhosis, pancreatitis, cardiac hypertrophy) [4][10][16].
High morbidity from diabetes complications, recurrent infections, and hypertrophic cardiomyopathy [4][8].
Reduced life expectancy without treatment; significant psychosocial impact due to physical stigma and chronic disease burden [10][16].
Therapies
Leptin replacement therapy (metreleptin) approved for generalized forms to improve metabolic control [8][13].
Aggressive management of comorbidities: insulin sensitizers (e.g., metformin), lipid-lowering agents, and dietary restriction of fats/carbohydrates [3][8][10].
Investigational approaches include adipose tissue transplantation and gene/cell therapies targeting adipocyte dysfunction [3][13].
Categories: rare developmental anomalies during embryogenesis, rare endocrine diseases, rare genetic diseases, rare neurological diseases, rare skin diseases
Research Papers
348 drug discovery papers about Congenital generalized lipodystrophy, with 4 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
348 drug discovery papers about Congenital generalized lipodystrophy, with 4 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-27 | Effect of metreleptin treatment in congenital generalized lipodystrophy: a retrospective analysis from the MENA region.
Congenital generalized lipodystrophy (CGL) is characterized by near-total loss of body fat, leptin deficiency, and severe metabolic complications. Clinical data show that metreleptin improves metabolic control in CGL; however, data from the Middle East and North Africa (MENA) is limited. We assessed the real-world effectiveness and safety of metreleptin in patients with CGL from this region. We conducted a multicenter, retrospective chart review of patients with CGL. Baseline, 6 ± 2months (short-term), 2 ± 1years (long-term), and >3 years follow-up data were analyzed. Median changes from baseline were calculated for short- and long-term assessments; >3 years data were reviewed individually. Safety was evaluated up to 90 days after last dose. Thirty-eight patients were included (82% female; median age at baseline, 6.3 years). Median treatment duration with metreleptin was 25 months (max dose, 10 mg/day). Significant short-term median reductions from baseline were observed for HbA1c (- 1.4%; n = 26), fasting plasma glucose (- 0.5 mmol/L; n = 21); fasting triglycerides (TG; -1.5 mmol/L; n = 26), alanine aminotransferase (- 18 IU/L, n = 27) and aspartate aminotransferase (- 7 IU/L, n = 27) (all p ≤ 0.02). These reductions were significant at long-term follow-up (p < 0.01) except for aspartate aminotransferase. At short-term follow-up, 50.0% of patients achieved ≥1% reduction in HbA1c and 65.4% had a ≥30% reduction in TG; corresponding long-term patient proportions were 46.7% and 61.5%. Most patients with >3 years follow-up showed improvement/maintenance of metabolic parameters. Overall, metreleptin was well tolerated with no new safety signals detected. Our findings support early intervention with metreleptin for sustained diabetes and hypertriglyceridemia control in CGL.
2026-07-23 | A Lean Metabolic Catastrophe - A Case Report on Congenital Generalized Lipodystrophy Presenting as Severe Insulin Resistance and Hypertriglyceridemia.
We report a 20-year-old female who presented with acute abdominal pain and vomiting, with a background of diabetes mellitus and severe hypertriglyceridemia since the age of 16 years. Clinical examination revealed a marked paucity of subcutaneous adipose tissue throughout the body. Laboratory investigations confirmed severe insulin resistance with HbA1c (glycated hemoglobin) of 8.5%, massive hypertriglyceridemia (1257 mg/dL), and preserved C-peptide levels (3.75 ng/mL). The clinical phenotype and biochemical profile suggested a diagnosis of congenital lipodystrophy, though genetic confirmation was not feasible due to financial constraints. Congenital lipodystrophy is characterized by ectopic fat accumulation in the liver, muscles, and pancreas, with resultant severe insulin resistance and metabolic complications. Management with dual PPAR agonist therapy (saroglitazar), omega-3 fatty acids (icosapent ethyl), thiazolidinediones (pioglitazone-metformin combination), and basal insulin resulted in significant improvement in lipid and glycemic parameters on subsequent follow-ups.
2026-07-16 | Congenital generalized lipodystrophy Type 2 (BSCL2; OMIM #269700) presenting with muscular hypertrophy and chronic steatorrhea in a Pakistani child: a pediatric case report confirmed by real-time PCR gene analysis
Abstract Background Congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, is a rare autosomal recessive condition with near-complete lack of metabolically functional adipocytes since birth or in early infancy, leading to severe metabolic complications. The prevalence of CGL is less than 1 case per million births, and it occurs in four genetic types (CGL1-CGL4). CGL type 2 (mutations in the BSCL2 gene; OMIM #269700) is the most common subtype (70–80% of cases), and has the most severe metabolic complications. Timely diagnosis is essential to avoid potentially fatal complications by early metabolic surveillance and treatment. Case presentation A 5.5-year-old Pakistani male child was referred for a muscular bodybuilder-like look since 24 months of age, chronic steatorrhea (4–5 times a day, aggravated by fat intake), hyperphagia, and poor growth. His birth was normal at term through a normal vaginal delivery and with normal weight and milestones. His family history was negative for lipodystrophy and metabolic disease. His weight (16 kg) and height (105 cm) were below 10th percentile with a BMI of 14.5 kg/m² (< 5th percentile). He had diffuse muscular hypertrophy with a complete loss of subcutaneous fat, visible veins, coarse face with facial lipoatrophy, abdominal distension with hepatomegaly (4 cm below the right costal margin, span 12 cm) and an everted umbilicus. There were no signs of acanthosis nigricans, xanthomas, hirsutism or splenomegaly. Real-Time PCR (RT-PCR) gene analysis confirmed CGL Type 2: BSCL2 exons 4 and 7 were detected; AGPAT2, CAV1, and PTRF were not detected. Both parents confirmed as carriers; all four siblings are unaffected (three heterozygous carriers, one non-carrier). Routine investigations showed macrocytic anaemia (Hb 10 g/dL, MCV 110.8 fL), raised transaminases (ALT 71 U/L, AST 97 U/L), grossly raised IgG (2727.98 mg/dL) and low IgA (4.39 mg/dL). Ultrasonography showed hepatic steatosis. Creatine phosphokinase (103 U/L) was normal, ruling out primary muscular dystrophy. IgA anti-tissue transglutaminase was negative, so coeliac disease was excluded. Hepatitis B, C and HIV were negative. Rickets and skeletal dysplasia were ruled out by a skeletal survey. Fasting triglycerides 862 mg/dL, serum leptin 0.4 ng/mL, and HOMA-IR 10.4 confirmed severe metabolic dysfunction characteristic of CGL2. Based on clinical and biochemical findings, RT-PCR confirmed the diagnosis of CGL type 2 (BSCL2; OMIM #269700) was made. A low-fat diet (20–30% of total energy) with medium-chain triglyceride supplementation, metabolic control and genetic counselling was started. Conclusions This RT-PCR confirmed case of CGL2 demonstrates the triad of CGL: diffuse lipoatrophy with muscular hypertrophy, hepatomegaly secondary to steatosis, and steatorrhoea, with poor growth. To our knowledge, this is the first RT-PCR confirmed CGL2 case reported from Pakistan. Early diagnosis of this rare condition is important to start life-changing metabolic interventions that include dietary restriction, metreleptin replacement and treatment of dyslipidaemia, which may dramatically impact the disease progression and outcome in childhood.
2026-06-01 | Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date.
Congenital generalized lipodystrophy (CGL) is a rare disorder marked by near-total loss of adipose tissue and severe metabolic disturbances due to leptin deficiency and the inability to store nutrients in adipose tissue effectively. Metreleptin is the only approved leptin replacement therapy for this condition. Here we present the >20-year follow-up of two sisters with CGL type 1 (AGPAT2 deficiency, OMIM# 608594), enrolled in early metreleptin trials. Clinical outcomes, adherence, immunogenicity, and pregnancies were assessed. Both cases showed rapid and sustained metabolic improvement after metreleptin initiation, allowing insulin discontinuation and triglyceride normalization. Menstrual cycles resumed within six months; allowing both to carry successful pregnancies while continuing metreleptin. Both cases experienced reduced treatment adherence over time, linked to psychological distress. One case developed both anti-drug antibodies and neutralizing activity through immune based assay after 14 years, but without significant clinical impact. In conclusion, these cases highlight both the sustained metabolic benefits of therapy and the complex challenges that may arise over time, such as antibody formation and difficulties in maintaining long-term adherence. Documentation of unmet medical needs can provide guidance and impetus for improved therapeutic approaches to achieve optimum quality of life.
2026-04-07 | AAV-mediated delivery of leptin but not adiponectin improves metabolic health in a mouse model of congenital generalised lipodystrophy
Lipodystrophies are a group of disorders featuring reduced adipose tissue mass or function, which often leads to significant metabolic disease, reduced lifespan and impaired quality of life. Individuals with congenital generalised lipodystrophy (CGL) have severely reduced adipose tissue mass. The loss of healthy systemic lipid storage typically causes hepatic steatosis and lipoatrophic diabetes. In addition, adipocyte-secreted hormones including leptin and adiponectin are dramatically reduced. Leptin has critical roles regulating appetite and broader effects on lipid and glucose metabolism. Daily injection with recombinant leptin is currently the only specific, approved treatment for CGL. The consequences of adiponectin loss in these patients are not fully understood. Likewise, the potential therapeutic benefit of adiponectin delivery is unclear. Here we examine the effect of delivering leptin or adiponectin by adeno-associated virus (AAV) as potential gene therapy treatment for metabolic disease in CGL using a well-characterised murine model of the condition. AAV mediated leptin delivery significantly improved hepatic steatosis and hyperinsulinemia. However, adiponectin delivery did not lead to any observed beneficial effects. This demonstrates the potential of gene therapy approaches for long-term delivery of leptin in individuals with lipodystrophy, without the need for continuous supply of perishable therapeutics and painful daily injections.
2026-07-27 | Effect of metreleptin treatment in congenital generalized lipodystrophy: a retrospective analysis from the MENA region.
Congenital generalized lipodystrophy (CGL) is characterized by near-total loss of body fat, leptin deficiency, and severe metabolic complications. Clinical data show that metreleptin improves metabolic control in CGL; however, data from the Middle East and North Africa (MENA) is limited. We assessed the real-world effectiveness and safety of metreleptin in patients with CGL from this region. We conducted a multicenter, retrospective chart review of patients with CGL. Baseline, 6 ± 2months (short-term), 2 ± 1years (long-term), and >3 years follow-up data were analyzed. Median changes from baseline were calculated for short- and long-term assessments; >3 years data were reviewed individually. Safety was evaluated up to 90 days after last dose. Thirty-eight patients were included (82% female; median age at baseline, 6.3 years). Median treatment duration with metreleptin was 25 months (max dose, 10 mg/day). Significant short-term median reductions from baseline were observed for HbA1c (- 1.4%; n = 26), fasting plasma glucose (- 0.5 mmol/L; n = 21); fasting triglycerides (TG; -1.5 mmol/L; n = 26), alanine aminotransferase (- 18 IU/L, n = 27) and aspartate aminotransferase (- 7 IU/L, n = 27) (all p ≤ 0.02). These reductions were significant at long-term follow-up (p < 0.01) except for aspartate aminotransferase. At short-term follow-up, 50.0% of patients achieved ≥1% reduction in HbA1c and 65.4% had a ≥30% reduction in TG; corresponding long-term patient proportions were 46.7% and 61.5%. Most patients with >3 years follow-up showed improvement/maintenance of metabolic parameters. Overall, metreleptin was well tolerated with no new safety signals detected. Our findings support early intervention with metreleptin for sustained diabetes and hypertriglyceridemia control in CGL.
2026-07-23 | A Lean Metabolic Catastrophe - A Case Report on Congenital Generalized Lipodystrophy Presenting as Severe Insulin Resistance and Hypertriglyceridemia.
We report a 20-year-old female who presented with acute abdominal pain and vomiting, with a background of diabetes mellitus and severe hypertriglyceridemia since the age of 16 years. Clinical examination revealed a marked paucity of subcutaneous adipose tissue throughout the body. Laboratory investigations confirmed severe insulin resistance with HbA1c (glycated hemoglobin) of 8.5%, massive hypertriglyceridemia (1257 mg/dL), and preserved C-peptide levels (3.75 ng/mL). The clinical phenotype and biochemical profile suggested a diagnosis of congenital lipodystrophy, though genetic confirmation was not feasible due to financial constraints. Congenital lipodystrophy is characterized by ectopic fat accumulation in the liver, muscles, and pancreas, with resultant severe insulin resistance and metabolic complications. Management with dual PPAR agonist therapy (saroglitazar), omega-3 fatty acids (icosapent ethyl), thiazolidinediones (pioglitazone-metformin combination), and basal insulin resulted in significant improvement in lipid and glycemic parameters on subsequent follow-ups.
2026-07-16 | Congenital generalized lipodystrophy Type 2 (BSCL2; OMIM #269700) presenting with muscular hypertrophy and chronic steatorrhea in a Pakistani child: a pediatric case report confirmed by real-time PCR gene analysis
Abstract Background Congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, is a rare autosomal recessive condition with near-complete lack of metabolically functional adipocytes since birth or in early infancy, leading to severe metabolic complications. The prevalence of CGL is less than 1 case per million births, and it occurs in four genetic types (CGL1-CGL4). CGL type 2 (mutations in the BSCL2 gene; OMIM #269700) is the most common subtype (70–80% of cases), and has the most severe metabolic complications. Timely diagnosis is essential to avoid potentially fatal complications by early metabolic surveillance and treatment. Case presentation A 5.5-year-old Pakistani male child was referred for a muscular bodybuilder-like look since 24 months of age, chronic steatorrhea (4–5 times a day, aggravated by fat intake), hyperphagia, and poor growth. His birth was normal at term through a normal vaginal delivery and with normal weight and milestones. His family history was negative for lipodystrophy and metabolic disease. His weight (16 kg) and height (105 cm) were below 10th percentile with a BMI of 14.5 kg/m² (< 5th percentile). He had diffuse muscular hypertrophy with a complete loss of subcutaneous fat, visible veins, coarse face with facial lipoatrophy, abdominal distension with hepatomegaly (4 cm below the right costal margin, span 12 cm) and an everted umbilicus. There were no signs of acanthosis nigricans, xanthomas, hirsutism or splenomegaly. Real-Time PCR (RT-PCR) gene analysis confirmed CGL Type 2: BSCL2 exons 4 and 7 were detected; AGPAT2, CAV1, and PTRF were not detected. Both parents confirmed as carriers; all four siblings are unaffected (three heterozygous carriers, one non-carrier). Routine investigations showed macrocytic anaemia (Hb 10 g/dL, MCV 110.8 fL), raised transaminases (ALT 71 U/L, AST 97 U/L), grossly raised IgG (2727.98 mg/dL) and low IgA (4.39 mg/dL). Ultrasonography showed hepatic steatosis. Creatine phosphokinase (103 U/L) was normal, ruling out primary muscular dystrophy. IgA anti-tissue transglutaminase was negative, so coeliac disease was excluded. Hepatitis B, C and HIV were negative. Rickets and skeletal dysplasia were ruled out by a skeletal survey. Fasting triglycerides 862 mg/dL, serum leptin 0.4 ng/mL, and HOMA-IR 10.4 confirmed severe metabolic dysfunction characteristic of CGL2. Based on clinical and biochemical findings, RT-PCR confirmed the diagnosis of CGL type 2 (BSCL2; OMIM #269700) was made. A low-fat diet (20–30% of total energy) with medium-chain triglyceride supplementation, metabolic control and genetic counselling was started. Conclusions This RT-PCR confirmed case of CGL2 demonstrates the triad of CGL: diffuse lipoatrophy with muscular hypertrophy, hepatomegaly secondary to steatosis, and steatorrhoea, with poor growth. To our knowledge, this is the first RT-PCR confirmed CGL2 case reported from Pakistan. Early diagnosis of this rare condition is important to start life-changing metabolic interventions that include dietary restriction, metreleptin replacement and treatment of dyslipidaemia, which may dramatically impact the disease progression and outcome in childhood.
2026-06-01 | Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date.
Congenital generalized lipodystrophy (CGL) is a rare disorder marked by near-total loss of adipose tissue and severe metabolic disturbances due to leptin deficiency and the inability to store nutrients in adipose tissue effectively. Metreleptin is the only approved leptin replacement therapy for this condition. Here we present the >20-year follow-up of two sisters with CGL type 1 (AGPAT2 deficiency, OMIM# 608594), enrolled in early metreleptin trials. Clinical outcomes, adherence, immunogenicity, and pregnancies were assessed. Both cases showed rapid and sustained metabolic improvement after metreleptin initiation, allowing insulin discontinuation and triglyceride normalization. Menstrual cycles resumed within six months; allowing both to carry successful pregnancies while continuing metreleptin. Both cases experienced reduced treatment adherence over time, linked to psychological distress. One case developed both anti-drug antibodies and neutralizing activity through immune based assay after 14 years, but without significant clinical impact. In conclusion, these cases highlight both the sustained metabolic benefits of therapy and the complex challenges that may arise over time, such as antibody formation and difficulties in maintaining long-term adherence. Documentation of unmet medical needs can provide guidance and impetus for improved therapeutic approaches to achieve optimum quality of life.
2026-04-07 | AAV-mediated delivery of leptin but not adiponectin improves metabolic health in a mouse model of congenital generalised lipodystrophy
Lipodystrophies are a group of disorders featuring reduced adipose tissue mass or function, which often leads to significant metabolic disease, reduced lifespan and impaired quality of life. Individuals with congenital generalised lipodystrophy (CGL) have severely reduced adipose tissue mass. The loss of healthy systemic lipid storage typically causes hepatic steatosis and lipoatrophic diabetes. In addition, adipocyte-secreted hormones including leptin and adiponectin are dramatically reduced. Leptin has critical roles regulating appetite and broader effects on lipid and glucose metabolism. Daily injection with recombinant leptin is currently the only specific, approved treatment for CGL. The consequences of adiponectin loss in these patients are not fully understood. Likewise, the potential therapeutic benefit of adiponectin delivery is unclear. Here we examine the effect of delivering leptin or adiponectin by adeno-associated virus (AAV) as potential gene therapy treatment for metabolic disease in CGL using a well-characterised murine model of the condition. AAV mediated leptin delivery significantly improved hepatic steatosis and hyperinsulinemia. However, adiponectin delivery did not lead to any observed beneficial effects. This demonstrates the potential of gene therapy approaches for long-term delivery of leptin in individuals with lipodystrophy, without the need for continuous supply of perishable therapeutics and painful daily injections.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
4 orphan drug designations for Congenital generalized lipodystrophy, including 2 approved therapies.
4 orphan drug designations for Congenital generalized lipodystrophy, including 2 approved therapies.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Mibavademab | antibodies | EMA | 2024-03-21 | — | Regeneron Ireland Designated Activity Company |
Metreleptin [Myalepta] | proteins | EMA | 2012-07-17 | 2018-08-01 | Chiesi Farmaceutici S.p.A. |
metreleptin | proteins | FDA | 2001-08-22 | — | Chiesi Farmaceutici S.p.A. |
metreleptin [MYALEPT] | proteins | FDA | 2001-08-22 | 2014-02-24 | Chiesi Farmaceutici S.p.A. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.